One of the novel aspects this review brings is the exploration of the effect of emerging HF pharmacotherapies, specifically sodium-glucose cotransporter-2 inhibitors (SGLT2i) and sacubitril/valsartan (S/V), on sleep parameters in OSA + HF patients. The gene discussed is SLC5A2; the disease is obstructive sleep apnea syndrome.